• Explore /
  • Poster
  • / Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).

Abstract Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN

Johanna C. Bendell , Tamara Sauri , Antonio Cubillo , Carlos López-López , Pilar Garcia Alfonso , Maen A. Hussein , M. Luisa Limon , Andres Cervantes , Clara Montagut , Cristina Santos , Alberto Bessudo , Manuel R. Modiano , Veerle Moons , Johannes Andel , Jaafar Bennouna , Andre Van Der Westhuizen , Leslie M. Samuel , Oliver Krieter , Simona Rossomanno , Herbert Hurwitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02141295

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3539)

DOI

10.1200/JCO.2017.35.15_suppl.3539

Abstract #

3539

Poster Bd #

162

Abstract Disclosures

Similar Posters

First Author: Marc Van Den Eynde

First Author: Jorge Riera-Knorrenschild

First Author: Maria Cortes

First Author: Ramon Salazar